Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKılıç, Adil
dc.contributor.authorErmiş, Sıtkı Samet
dc.contributor.authorSarı, Esin
dc.contributor.authorYazıcı, Alper
dc.date.accessioned2019-11-22T07:49:18Z
dc.date.available2019-11-22T07:49:18Z
dc.date.issued2015en_US
dc.identifier.issn1304-3889
dc.identifier.issn1304-3897
dc.identifier.urihttps://doi.org/10.15197/ejgm.01385
dc.identifier.urihttps://hdl.handle.net/20.500.12462/10034
dc.description.abstractBranch retinal vein occlusion related macular edema (BRVO-ME) is the leading cause of visual loss in patients with Branch retinal vein occlusion (BRVO). In the current study, our aim was to investigate the outcome of intravitreal ranibizumab injection for BRVO-ME. The medical records of randomised thirteen eyes of thirteen patients (7 women and 6 men) with BRVO-ME were reviewed retrospectively. Three and 10 eyes had inferior temporal and superior temporal branch retinal vein occlusion-related macular edema, respectively. At the enrollment visit, all patients received a complete ophthalmic examination, including central subfield (CSF) thickness and average cube thickness measurements using spectral-domain optical coherence tomography (SD-OCT), best corrected visual acuity (BCVA) and intraocular pressure (IOP) measurements. The median patient age was 53 years (range, 38-74). Of the patients, median CSF thickness was 453 mu (range, 221-907), median average cube thickness was 293 mu (range, 237-433), median BCVA was 0.30 logMAR unit (range, 0.05-1.00 logMAR unit), and median IOP scores was 18 mmHg (range, 15-25) at baseline. Compared with baseline, a statistical significance in median CSF thickness scores at week 1 (p= 0.015), months 1 (p= 0.015), 2 (p= 0.030), and 3 (p= 0.045) was noted. Compared with baseline, a statistical significance in median BCVA scores at months 2 (p= 0.045), 3 (p= 0.030), and 6 (p= 0.045) was noted. Compared with baseline, no statistical significance in median IOP scores and median average cube thickness scores at week 1, months 1, 2, 3, and 6 was noted (p> 0.05, for all). No statistical significance in median CSF thickness scores, median BCVA scores, median IOP scores, or median average cube thickness scores was noted between the other follow-up periods. No complication related to ranibizumab injections was detected during the follow-up period. The treatment method does not cause any increase in IOP score. Besides ranibizumab injection can cause a dramatic decrease in CSF thickness scores and a dramatic increase in BCVA scores as early as at week 1 postoperatively.en_US
dc.language.isoengen_US
dc.publisherModestum Ltden_US
dc.relation.isversionof10.15197/ejgm.01385en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBranch Retinal Vein Occlusionen_US
dc.subjectMacular Edemaen_US
dc.subjectRanibizumaben_US
dc.titleThe outcome of intravitreal ranibizumab injection for branch retinal vein occlusion related macular edemaen_US
dc.title.alternativeRetina ven tıkanıklığına bağlı makula ödeminde intravitreal ranibizumab enjeksiyonun sonuçlarıen_US
dc.typearticleen_US
dc.relation.journalEuropean Journal of General Medicineen_US
dc.contributor.departmentTıp Fakültesien_US
dc.identifier.volume12en_US
dc.identifier.issue3en_US
dc.identifier.startpage199en_US
dc.identifier.endpage202en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster